港股異動 | 遠大醫藥升超20%,高瓴資本有望成潛在承配人
uSMART友信智投8月3日消息,週一港股,遠大醫藥大幅高開,截至11:05分,市中最高升20.16%,報8.82港元。
遠大醫藥(00512)發佈公告,於2020年8月1日,該公司與配售代理訂立配售協定,配售代理已有條件同意作為公司的代理,按每股配售股份5.90 港元的配售價格配售最多1.72億股新股份。
預期將會有不少於六名承配人,高瓴資本是潛在承配人之一。
配售股份數目相當於本公司已發行股本約5.09%,待配售事項如期完成後,配售事項所得款項總額預期約10.15億港元,所得款項淨額則約10.14億港元。每股配售股份的配售價格港幣5.90元,較7月31日每股股份收市價7.34港元折讓約19.62%
據悉,該集團主要從事研發、製造及銷售醫藥製劑、醫療器械、特色原料藥以及健康產品。公司計畫將配售事項所得款項淨額用於研發項目,包括但不限於現有及未來的國內及海外藥品研發、擴充研發團隊及於技術的投資,預期可以進一步增強研發能力及豐富產品管線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.